Valuation: Mymetics Corporation

Market Cap 439K 381K 354K 325K 615K 41.85M 625K 4.17M 1.64M 20.84M 1.65M 1.61M 69.06M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.56M 58.23M 53.5M 101M 6.88B 103M 686M 270M 3.43B 271M 265M 11.35B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
29.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-85.45% 45
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%-1.61%-17.69%-15.68% 23.48B
-2.85%-8.20%-6.26%+361.83% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.25%-4.71%+43.89%+167.15% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average +4.43%-1.29%+106,688.82%+133.94% 23.34B
Weighted average by Cap. +0.17%+0.09%+31.05%+122.81%

Financials

2021 2022
Net sales 430K 373K 347K 319K 603K 41.01M 612K 4.09M 1.61M 20.43M 1.61M 1.58M 67.68M 1.03M 892K 830K 763K 1.44M 98.05M 1.46M 9.78M 3.84M 48.84M 3.86M 3.78M 162M
Net income -4.73M -4.1M -3.82M -3.51M -6.63M -451M -6.74M -44.98M -17.68M -225M -17.76M -17.37M -745M -4.8M -4.17M -3.88M -3.56M -6.74M -458M -6.84M -45.69M -17.96M -228M -18.04M -17.65M -756M
Net Debt 67.1M 58.21M 54.18M 49.78M 94.05M 6.4B 95.57M 638M 251M 3.19B 252M 246M 10.56B 71.68M 62.18M 57.88M 53.18M 100M 6.84B 102M 682M 268M 3.41B 269M 263M 11.28B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock